Literature DB >> 1974181

Activation antigens expressed on T-cells of the peripheral blood in Sjögren's syndrome and rheumatoid arthritis.

Y Ichikawa1, H Shimizu, M Yoshida, S Arimori.   

Abstract

We analyzed activated T-cells in the peripheral blood (PB) of 29 patients with Sjögren's syndrome (SS: 13 I degrees-SS and 16 II degrees-SS patients) and 11 patients with rheumatoid arthritis (RA) by two-color flowcytometry using antibodies to antigens serially expressed on the cell surface after activation--interleukin-2 receptor (IL-2R), HLA-DR, T-lineage specific antigen (TLiSA-1) and very late antigen (VLA-1). The early and intermediate activation antigens, DR and TLiSA-1, were significantly increased in the PB of SS and/or RA patients. The proportions of activated T-cells were higher in CD8+ cells than those in CD4+ cells. T-cells expressing IL-2R or VLA-1, which appear in the very early or late stages of activation, were also increased in SS and/or RA patients. The results suggest that activated T-cells in the PB of both diseases might be recruited from continuously activated lymphoid organs, and that the activated cells migrate from PB into target tissues. In addition, the increase of activated T-cells in PB might be one of the causes of the deficient cell-mediated immunity reported in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974181

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features.

Authors:  K Eguchi; N Matsuoka; H Ida; M Nakashima; M Sakai; S Sakito; A Kawakami; K Terada; H Shimada; Y Kawabe
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.

Authors:  B Berner; G Wolf; K M Hummel; G A Müller; M A Reuss-Borst
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 3.  Immune cell profiling to guide therapeutic decisions in rheumatic diseases.

Authors:  Joerg Ermann; Deepak A Rao; Nikola C Teslovich; Michael B Brenner; Soumya Raychaudhuri
Journal:  Nat Rev Rheumatol       Date:  2015-06-02       Impact factor: 20.543

4.  HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease.

Authors:  Seth P Epstein; Neha Gadaria-Rathod; Yi Wei; Maureen G Maguire; Penny A Asbell
Journal:  Exp Eye Res       Date:  2013-04-06       Impact factor: 3.467

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.